Frontier Communications Corporation (NASDAQ:FTR) shares advanced 2.71% in last trading session and ended the day at $4.54. FTR Gross Margin is 50.70% and its has a return on assets of -0.70%. Frontier Communications Corporation (NASDAQ:FTR) quarterly performance is -2.52%.
Frontier Communications Corporation (NASDAQ:FTR) announced that its Board of Directors has declared a regular quarterly dividend on Frontier’s 11.125% Mandatory Convertible Preferred Stock, Series A, of $2.78125 per share, payable in cash on March 31, 2016 to holders of record at the close of business on March 11, 2016.
GW Pharmaceuticals plc (NASDAQ:GWPH) ended the last trading day at $44.94. Company weekly volatility is calculated as 7.24% and price to cash ratio as 2.79. GW Pharmaceuticals plc (NASDAQ:GWPH) showed a weekly performance of 3.03%.
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased GW Pharmaceuticals plc (NASDAQ:GWPH) securities between December 4, 2014 and January 8, 2016.
On 18 February, Bazaarvoice, Inc. (NASDAQ:BV) shares moved down -2.30% and was closed at $2.97. BV EPS growth in last 5 year was -24.60%. Bazaarvoice, Inc. (NASDAQ:BV) year to date (YTD) performance is -32.19%.
Bazaarvoice, Inc. (NASDAQ:BV), announced that it will release financial results for the third fiscal quarter ended January 31, 2016 after market close on Tuesday, March 1, 2016. The Company will host a conference call at 4:30 p.m. Eastern Time on the same day to review the Company’s financial results and operations.
Repros Therapeutics Inc. (NASDAQ:RPRX) shares moved down -0.54% in last trading session and ended the day at $0.93. RPRX has a return on assets of -85.30%. Repros Therapeutics Inc. (NASDAQ:RPRX) quarterly performance is -41.08%.
Repros Therapeutics Inc.® (NASDAQ:RPRX) announced that on February 4, 2016, the Company attended a productive meeting with FDA reviewers and senior leaders to discuss resolution of issues identified during the enclomiphene NDA review. The meeting agenda covered a broad range of topics surrounding the NDA data as well as emerging Agency and expert thinking regarding the treatment of hypogonadism. The Company believes that it was clear during the meeting that the FDA is not closed to entertaining secondary hypogonadism as an indication.
Weight Watchers International, Inc. (NYSE:WTW) caters to the Services space. It has a net profit margin of 3.90% and weekly performance is 13.09%. On the last day of trading company shares ended up at $12.61. Weight Watchers International, Inc. (NYSE:WTW) distance from 50-day simple moving average (SMA50) is -25.18%.
Weight Watchers International, Inc. (NYSE:WTW) will release its results for the fourth quarter and full year 2015 after the NYSE closes on Thursday, February 25, 2016.
Leave a Reply